CoChat

CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations

Open access

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index; none of the 42 sources its claims cite is checked for support yet.

Abstract

CBS domains are defined as sequence motifs that occur in several different proteins in all kingdoms of life. Although thought to be regulatory, their exact functions have been unknown. However, their importance was underlined by findings that mutations in conserved residues within them cause a variety of human hereditary diseases, including (with the gene mutated in parentheses): Wolff-Parkinson-White syndrome (gamma 2 subunit of AMP-activated protein kinase); retinitis pigmentosa (IMP dehydrogenase-1); congenital myotonia, idiopathic generalized epilepsy, hypercalciuric nephrolithiasis, and classic Bartter syndrome (CLC chloride channel family members); and homocystinuria (cystathionine beta-synthase). AMP-activated protein kinase is a sensor of cellular energy status that is activated by AMP and inhibited by ATP, but the location of the regulatory nucleotide-binding sites (which are prime targets for drugs to treat obesity and diabetes) was not characterized. We now show that tandem pairs of CBS domains from AMP-activated protein kinase, IMP dehydrogenase-2, the chloride channel CLC2, and cystathionine beta-synthase bind AMP, ATP, or S-adenosyl methionine,while mutations that cause hereditary diseases impair this binding. This shows that tandem pairs of CBS domains act, in most cases, as sensors of cellular energy status and, as such, represent a newly identified class of binding domain for adenosine derivatives.

Overview

CoChat Summary

## TL;DR

This paper shows that tandem CBS domain pairs act as allosteric binding modules for adenosine-related ligands, including AMP and ATP in AMPK, ATP in IMPDH and CLC2, and SAM in cystathionine β-synthase. It also shows that disease-associated mutations in these domains weaken ligand binding and, in AMPK, impair AMP-dependent activation.

## Key findings

  • For AMPKγ2, the isolated CBS1-2 pair bound 1 AMP molecule with Kd = 53 ± 5 µM, and the CBS3-4 pair bound 1 AMP molecule with Kd = 104 ± 10 µM; the full CBS1-4 construct bound 2 AMP molecules with B0.5 = 61 ± 2 µM and Hill coefficient = 2.2 ± 0.1.
  • Disease mutations increased AMP binding constants for AMPKγ2 CBS constructs; for CBS1-4, B0.5 for AMP rose from 61 ± 2 µM (WT) to 158 ± 9 µM (R302Q), 725 ± 36 µM (H383R), 1,360 ± 47 µM (T400N), and 2,800 ± 220 µM (R531G).
  • In recombinant α1β1γ2 AMPK heterotrimers, the A0.5 for AMP activation increased in the same order as binding defects: WT 7 ± 3 µM, L ins 9 ± 4 µM, R302Q 23 ± 6 µM, H383R 51 ± 40 µM, T400N 95 ± 32 µM, and R531G >100 µM; the paper also states the WT α1β1γ1, α1β1γ2, and α1β1γ3 complexes were stimulated 3.3-fold, 7.0-fold, and 1.5-fold by AMP, respectively.
  • Other CBS-domain proteins showed the same pattern: IMPDH2 CBS domains bound 1 ATP molecule with Kd = 54 ± 6 µM, while the R224P mutation increased this to 450 ± 36 µM; full-length IMPDH2 bound ATP with B0.5 = 770 ± 50 µM and ATP stimulated IMPDH activity more than fourfold with A0.5 = 0.44 ± 0.05 mM and Hill coefficient = 1.3 ± 0.1; CLC2 CBS domains bound ATP with Kd = 1.06 ± 0.08 mM, and pathogenic mutations raised this to 10.4-fold (G715E) and 14-fold (G826D) higher; cystathionine β-synthase CBS domains bound SAM with Kd = 34 ± 2 µM, and D444N increased this 15-fold to 510 ± 70 µM.

## Methods

  • The study cloned CBS-domain constructs from AMPKγ1, γ2, and γ3, IMPDH2, CLC2, and cystathionine β-synthase, expressed them mainly as GST fusions in bacteria, and introduced disease mutations by site-directed mutagenesis.
  • Ligand binding was measured using radiolabeled AMP, ATP, or SAM with rapid filtration, and data were fit to single-site or Hill binding models; AMPK heterotrimers were also expressed in CCL13 cells and assayed for AMP-dependent activity after rapid or slow lysis.
  • IMPDH2 enzymatic activity was measured by NADH formation at 340 nm in the presence or absence of ATP.

## Limitations

  • The paper itself notes several unresolved issues: AMP activation of AMPK heterotrimers occurred at concentrations about tenfold lower than the B0.5 values for AMP binding to isolated CBS1-4 constructs; the three AMPKγ isoforms differed in AMP binding (20 µM, 53 µM, 125 µM) but the heterotrimers differed mainly in degree of stimulation rather than A0.5; and it states that further work is required to determine whether AMPK uses a mechanism similar to cAMP-dependent protein kinase.
  • The text makes evident that some activation estimates are less precise because AMP could not be tested above 100 µM in heterotrimer assays, and the authors say the A0.5 values for H383R and T400N are less accurate, while no A0.5 could be obtained for R531G; this is an evidence-based limitation from the assay design.
  • The study used purified domains and recombinant proteins in bacteria or cell culture, so direct in vivo physiology is not tested here; this is evident from the methods and experimental system, not explicitly stated as a limitation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci19874

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 23 Not checked · 78 Own results and interpretations

49 more claims

Create a free account to see all 101 claims and to verify the 42 references still open.

See all claims — free account
  • It may state two separate claims as one. 38
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

1 retracted

Research works printed but not linked: 4

  1. Winder, 1996, Am. J. Physiol., 270, E299
  2. Merrill, 1997, Am. J. Physiol., 273, E1107
  3. Winder, 1999, Am. J. Physiol., 277, E1
  4. Hardie, 2000, Methods Mol. Biol., 99, 63

Cited by

See all 754

Metadata

Authors
Scott, J. W., Hawley, S. A., Green, K. A., Anis, M., Stewart, G., Scullion, G. A., Norman, D. G., & Hardie, D. G.
Affiliations
University of Dundee (GB)
Venue
Journal of Clinical Investigation
Published
2004-01-15
Volume
113
Issue
2
Pages
274-284
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2166714586
Cited by
754
References
56
Citations by year
2026: 13 · 2025: 17 · 2024: 19 · 2023: 16 · 2022: 18 · 2021: 19 · 2020: 19 · 2019: 23 · 2018: 27 · 2017: 37 · 2016: 25 · 2015: 22 · 2014: 33 · 2013: 35 · 2012: 59
FWCI
21.36
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
  • Wellcome Trust (QLG1-CT-2001-01488)
  • European Commission
  • Directorate for Biological Sciences
  • Biotechnology and Biological Sciences Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
Keywords
CBS domain, energy sensing, AMPK, cystathionine beta-synthase, S-adenosylmethionine, pathogenic variants, genetic disorders, nucleotide binding site
MeSH terms
Adenosine, Adenosine Monophosphate, Adenosine Triphosphate, Allosteric Site, Animals, Binding Sites, Cloning, Molecular, DNA, Dose-Response Relationship, Drug, Escherichia coli, Glutathione Transferase, Humans, Kinetics, Ligands, Liver, Models, Molecular, Mutation, Plasmids, Protein Binding, Recombinant Fusion Proteins, Recombinant Proteins, Retinitis Pigmentosa, Polymerase Chain Reaction, Protein Structure, Tertiary, DNA, Complementary, Dimerization, Protein Isoforms, Amino Acid Motifs, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.